These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38671056)

  • 1. First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer.
    Mullard A
    Nat Rev Drug Discov; 2024 Jun; 23(6):410. PubMed ID: 38671056
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab Gets FDA Nod for Bladder Cancer.
    Cancer Discov; 2017 Apr; 7(4):OF7. PubMed ID: 28183696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutics: Spoilt for choice.
    Eisenstein M
    Nature; 2017 Nov; 551(7679):S36-S38. PubMed ID: 29117155
    [No Abstract]   [Full Text] [Related]  

  • 4. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.
    Davies BJ; Hwang TJ; Kesselheim AS
    N Engl J Med; 2017 Apr; 376(15):1401-1403. PubMed ID: 28402764
    [No Abstract]   [Full Text] [Related]  

  • 5. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
    Parikh RB; Adamson BJS; Khozin S; Galsky MD; Baxi SS; Cohen A; Mamtani R
    JAMA; 2019 Sep; 322(12):1209-1211. PubMed ID: 31550019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approves Eribulin for Advanced Liposarcoma.
    Landhuis E
    Cancer Discov; 2016 Mar; 6(3):OF1. PubMed ID: 26842649
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approval of the first cellular therapy for a solid (non-hematologic) cancer.
    Kochenderfer JN
    Mol Ther; 2024 Apr; 32(4):857-858. PubMed ID: 38503296
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of the fDA in cancer clinical trials.
    Hirschfeld S
    Cancer Treat Res; 2007; 132():51-109. PubMed ID: 17305017
    [No Abstract]   [Full Text] [Related]  

  • 11. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 12. While We're at It, Let's Whack the FDA.
    Chabner BA
    Oncologist; 2016 Mar; 21(3):259-60. PubMed ID: 26869585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
    Bach PB; Giralt SA; Saltz LB
    JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
    [No Abstract]   [Full Text] [Related]  

  • 14. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
    Pilon D; Ellis LA; Xiao Y; Behl AS; Lefebvre P
    Am J Ther; 2019; 26(3):e422-e424. PubMed ID: 30677005
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA announces fast track approval of new drug for lung cancer.
    Dyer O
    BMJ; 2003 May; 326(7397):1004. PubMed ID: 12742913
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA approves new drug for specific type of advanced breast cancer.
    Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
    [No Abstract]   [Full Text] [Related]  

  • 17. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer drugs remain FDA approved despite lack of benefit, study finds.
    McCarthy M
    BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
    [No Abstract]   [Full Text] [Related]  

  • 19. Bladder cancer immunotherapy: swinging for the fences.
    Aoun F; El Rassy E; Peltier A
    Future Oncol; 2017 Apr; 13(9):773-775. PubMed ID: 28183191
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA accelerated approval benefits glioblastoma.
    Cloughesy T
    Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.